Clinical Outcomes of Treatment of Geographic Atrophy: A Narrative Review

被引：0

作者：

Anne Helene Køllund Nissen ^{[1
]}

Thomas Lee Torp ^{[2
]}

Anna Stage Vergmann ^{[2
]}

机构：

[1] Research Unit of Ophthalmology, Department of Ophthalmology, Odense University Hospital, J. B. Winsløws Vej 4, Odense C

[2] Department of Clinical Research, University of Southern Denmark, Odense

[3] Department of Ophthalmology, Vejle Hospital, Vejle

来源：

Ophthalmology and Therapy | 2025年 / 14卷 / 6期

关键词：

ACP; AMD; Avacincaptad pegol; Dietary supplementation; Geographic atrophy; Pegcetacoplan; Photobiomodulation; Treatment;

D O I：

10.1007/s40123-025-01144-9

中图分类号：

学科分类号：

摘要：

Rationale: In 2023, the U.S. Food and Drug Administration approved pegcetacoplan (SYFOVRE) as the first therapeutic option for geographic atrophy (GA), a previously untreatable condition associated with age-related macular degeneration. Following this, avacincaptad pegol (Izervay) was also approved for GA treatment, further expanding therapeutic options. Objectives: This article aims to give an overview of the clinical outcomes of GA treatment and to discuss which patient groups may benefit most from these therapies. Methods: A review of the literature was conducted using the databases PubMed, Cochrane Library, and ClinicalTrials.gov. The search yielded six relevant studies. Conclusions: The management of geographic atrophy has advanced with therapies like pegcetacoplan and avacincaptad pegol showing clear benefits in slowing lesion growth. However, safety concerns, such as neovascular complications, persist. Photobiomodulation and dietary supplementation provide alternative options with modest benefits, particularly in the early stages. Larger studies are needed to confirm long-term safety, efficacy, and optimal treatment strategies. © The Author(s) 2025.

引用

页码：1173 / 1181

页数：8

共 27 条

[1] Wong W.L., Su X., Li X., Et al., Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis, Lancet Glob Health, 2, 2, pp. e106-e116, (2014)
[2] Fonteh C.N., Mathias M.T., Mandava N., Et al., Mental health and visual acuity in patients with age-related macular degeneration, BMC Ophthalmol, 22, 1, (2022)
[3] Assi L., Chamseddine F., Ibrahim P., Et al., A global assessment of eye health and quality of life: a systematic review of systematic reviews, JAMA Ophthalmol, 139, 5, pp. 526-541, (2021)
[4] Rozing M.P., Durhuus J.A., Krogh Nielsen M., Et al., Age-related macular degeneration: a two-level model hypothesis, Prog Retin Eye Res, 76, (2020)
[5] Mitchell P., Liew G., Gopinath B., Wong T.Y., Age-related macular degeneration, Lancet, 392, pp. 1147-1159, (2018)
[6] SanGiovanni J.P., Chew E.Y., Clemons T.E., Et al., The relationship of dietary carotenoid and vitamin A, E, and C intake with age-related macular degeneration in a case-control study: AREDS Report No. 22, Arch Ophthalmol, 125, 9, pp. 1225-1232, (2007)
[7] Thornton J., Edwards R., Mitchell P., Harrison R.A., Buchan I., Kelly S.P., Smoking and age-related macular degeneration: a review of association, Eye (Lond), 19, 9, pp. 935-944, (2005)
[8] Fu D.J., Bagga P., Naik G., Et al., Pegcetacoplan treatment and consensus features of geographic atrophy over 24 months, JAMA Ophthalmol, 142, 6, pp. 548-558, (2024)
[9] Danzig C.J., Khanani A.M., Kaiser P.K., Et al., Vision loss reduction with avacincaptad pegol for geographic atrophy: a 12-month post hoc analysis of the GATHER1 and GATHER2 trials, Ophthalmol Retina, 8, 11, pp. 1052-1060, (2024)
[10] Patel S.S., Lally D.R., Hsu J., Et al., Avacincaptad pegol for geographic atrophy secondary to age-related macular degeneration: 18-month findings from the GATHER1 trial, Eye (Lond), 37, 17, pp. 3551-3557, (2023)

← 1 2 3 →